These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
317 related articles for article (PubMed ID: 30061636)
1. GPR55 signalling promotes proliferation of pancreatic cancer cells and tumour growth in mice, and its inhibition increases effects of gemcitabine. Ferro R; Adamska A; Lattanzio R; Mavrommati I; Edling CE; Arifin SA; Fyffe CA; Sala G; Sacchetto L; Chiorino G; De Laurenzi V; Piantelli M; Sansom OJ; Maffucci T; Falasca M Oncogene; 2018 Dec; 37(49):6368-6382. PubMed ID: 30061636 [TBL] [Abstract][Full Text] [Related]
2. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia. McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621 [TBL] [Abstract][Full Text] [Related]
3. Synergistic Pharmacodynamic Effects of Gemcitabine and Fibroblast Growth Factor Receptor Inhibitors on Pancreatic Cancer Cell Cycle Kinetics and Proliferation. Lin Q; Qian Z; Jusko WJ; Mager DE; Ma WW; Straubinger RM J Pharmacol Exp Ther; 2021 Jun; 377(3):370-384. PubMed ID: 33753538 [TBL] [Abstract][Full Text] [Related]
4. In Vitro and In Vivo Effects of Melatonin-Containing Combinations in Human Pancreatic Ductal Adenocarcinoma. Zeppa L; Aguzzi C; Morelli MB; Marinelli O; Amantini C; Giangrossi M; Santoni G; Fanelli A; Luongo M; Nabissi M J Pineal Res; 2024 Aug; 76(5):e12997. PubMed ID: 39076059 [TBL] [Abstract][Full Text] [Related]
5. Modulation of Cancer-Associated Fibrotic Stroma by An Integrin α Turaga RC; Sharma M; Mishra F; Krasinskas A; Yuan Y; Yang JJ; Wang S; Liu C; Li S; Liu ZR Cell Mol Gastroenterol Hepatol; 2021; 11(1):161-179. PubMed ID: 32810598 [TBL] [Abstract][Full Text] [Related]
6. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer. Zhu H; Gao W; Li X; Yu L; Luo D; Liu Y; Yu X Pancreatology; 2021 Apr; 21(3):589-598. PubMed ID: 33579599 [TBL] [Abstract][Full Text] [Related]
7. Anti-stromal treatment together with chemotherapy targets multiple signalling pathways in pancreatic adenocarcinoma. Carapuça EF; Gemenetzidis E; Feig C; Bapiro TE; Williams MD; Wilson AS; Delvecchio FR; Arumugam P; Grose RP; Lemoine NR; Richards FM; Kocher HM J Pathol; 2016 Jul; 239(3):286-96. PubMed ID: 27061193 [TBL] [Abstract][Full Text] [Related]
8. Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II. Awasthi N; Zhang C; Hinz S; Schwarz MA; Schwarz RE J Exp Clin Cancer Res; 2013 Mar; 32(1):12. PubMed ID: 23497499 [TBL] [Abstract][Full Text] [Related]
9. pH-responsive targeted nanoparticles release ERK-inhibitor in the hypoxic zone and sensitize free gemcitabine in mutant K-Ras-addicted pancreatic cancer cells and mouse model. Dutta D; Ray P; De A; Ghosh A; Hazra RS; Ghosh P; Banerjee S; Diaz FJ; Upadhyay SP; Quadir M; Banerjee SK PLoS One; 2024; 19(4):e0297749. PubMed ID: 38687749 [TBL] [Abstract][Full Text] [Related]
10. Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma. Borsoi C; Leonard F; Lee Y; Zaid M; Elganainy D; Alexander JF; Kai M; Liu YT; Kang Y; Liu X; Koay EJ; Ferrari M; Godin B; Yokoi K Cancer Lett; 2017 Sep; 403():296-304. PubMed ID: 28687352 [TBL] [Abstract][Full Text] [Related]
11. Molecular analysis of XPO1 inhibitor and gemcitabine-nab-paclitaxel combination in KPC pancreatic cancer mouse model. Uddin MH; Al-Hallak MN; Khan HY; Aboukameel A; Li Y; Bannoura SF; Dyson G; Kim S; Mzannar Y; Azar I; Odisho T; Mohamed A; Landesman Y; Kim S; Beydoun R; Mohammad RM; Philip PA; Shields AF; Azmi AS Clin Transl Med; 2023 Dec; 13(12):e1513. PubMed ID: 38131168 [TBL] [Abstract][Full Text] [Related]
12. Anti-tumour efficacy of capecitabine in a genetically engineered mouse model of pancreatic cancer. Courtin A; Richards FM; Bapiro TE; Bramhall JL; Neesse A; Cook N; Krippendorff BF; Tuveson DA; Jodrell DI PLoS One; 2013; 8(6):e67330. PubMed ID: 23840665 [TBL] [Abstract][Full Text] [Related]
13. RCC1 regulation of subcellular protein localization via Ran GTPase drives pancreatic ductal adenocarcinoma growth. Bannoura SF; Aboukameel A; Khan HY; Uddin MH; Jang H; Beal EW; Thangasamy A; Shi Y; Kim S; Wagner KU; Beydoun R; El-Rayes BF; Philip PA; Mohammad RM; Saif MW; Al-Hallak MN; Pasche BC; Azmi AS Cancer Lett; 2024 Nov; 604():217275. PubMed ID: 39321913 [TBL] [Abstract][Full Text] [Related]
14. Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer. Venkatasubbarao K; Peterson L; Zhao S; Hill P; Cao L; Zhou Q; Nawrocki ST; Freeman JW Mol Cancer; 2013 Sep; 12(1):104. PubMed ID: 24025152 [TBL] [Abstract][Full Text] [Related]
15. IL1 Receptor Antagonist Inhibits Pancreatic Cancer Growth by Abrogating NF-κB Activation. Zhuang Z; Ju HQ; Aguilar M; Gocho T; Li H; Iida T; Lee H; Fan X; Zhou H; Ling J; Li Z; Fu J; Wu M; Li M; Melisi D; Iwakura Y; Xu K; Fleming JB; Chiao PJ Clin Cancer Res; 2016 Mar; 22(6):1432-44. PubMed ID: 26500238 [TBL] [Abstract][Full Text] [Related]
16. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer. Nagathihalli NS; Castellanos JA; Shi C; Beesetty Y; Reyzer ML; Caprioli R; Chen X; Walsh AJ; Skala MC; Moses HL; Merchant NB Gastroenterology; 2015 Dec; 149(7):1932-1943.e9. PubMed ID: 26255562 [TBL] [Abstract][Full Text] [Related]
17. Brucein D augments the chemosensitivity of gemcitabine in pancreatic cancer via inhibiting the Nrf2 pathway. Zhang J; Xu HX; Cho WCS; Cheuk W; Li Y; Huang QH; Yang W; Xian YF; Lin ZX J Exp Clin Cancer Res; 2022 Mar; 41(1):90. PubMed ID: 35272669 [TBL] [Abstract][Full Text] [Related]
18. Metformin suppresses tumor angiogenesis and enhances the chemosensitivity of gemcitabine in a genetically engineered mouse model of pancreatic cancer. Qian W; Li J; Chen K; Jiang Z; Cheng L; Zhou C; Yan B; Cao J; Ma Q; Duan W Life Sci; 2018 Sep; 208():253-261. PubMed ID: 30053447 [TBL] [Abstract][Full Text] [Related]
19. BRD4 promotes pancreatic ductal adenocarcinoma cell proliferation and enhances gemcitabine resistance. Wang YH; Sui YN; Yan K; Wang LS; Wang F; Zhou JH Oncol Rep; 2015 Apr; 33(4):1699-706. PubMed ID: 25647019 [TBL] [Abstract][Full Text] [Related]
20. Cadherin 11 Promotes Immunosuppression and Extracellular Matrix Deposition to Support Growth of Pancreatic Tumors and Resistance to Gemcitabine in Mice. Peran I; Dakshanamurthy S; McCoy MD; Mavropoulos A; Allo B; Sebastian A; Hum NR; Sprague SC; Martin KA; Pishvaian MJ; Vietsch EE; Wellstein A; Atkins MB; Weiner LM; Quong AA; Loots GG; Yoo SS; Assefnia S; Byers SW Gastroenterology; 2021 Mar; 160(4):1359-1372.e13. PubMed ID: 33307028 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]